Cargando…
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Pemetrexed (PEM) is a useful drug that can be combined with immune checkpoint blockade therapy for treatment of patients with advanced non–small‐cell lung cancer (NSCLC). However, its effects on anti–cancer immunity, especially the sensitivity of NSCLC cells to cytotoxic immune cells, have not been...
Autores principales: | Okimoto, Tamio, Kotani, Hitoshi, Iida, Yuichi, Koyanagi, Akira, Tanino, Ryosuke, Tsubata, Yukari, Isobe, Takeshi, Harada, Mamoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293070/ https://www.ncbi.nlm.nih.gov/pubmed/32232903 http://dx.doi.org/10.1111/cas.14401 |
Ejemplares similares
-
Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity
por: Inao, Touko, et al.
Publicado: (2019) -
Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
por: Tanino, Ryosuke, et al.
Publicado: (2018) -
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018) -
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019) -
Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor‐induced senescence in breast cancer cells
por: Kartika, Irna D., et al.
Publicado: (2021)